Leow Jeffrey J, Cole Alexander P, Seisen Thomas, Bellmunt Joaquim, Mossanen Matthew, Menon Mani, Preston Mark A, Choueiri Toni K, Kibel Adam S, Chung Benjamin I, Sun Maxine, Chang Steven L, Trinh Quoc-Dien
Division of Urologic Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Urology, Tan Tock Seng Hospital, Singapore.
Division of Urologic Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Eur Urol. 2018 Mar;73(3):374-382. doi: 10.1016/j.eururo.2017.07.016. Epub 2017 Aug 10.
Radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) has potential for serious complications, prolonged length of stay and readmissions-all of which may increase costs. Although variations in outcomes are well described, less is known about determinants driving variation in costs.
To assess surgeon- and hospital-level variations in costs and predictors of high- and low-cost RC.
DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 23 173 patients who underwent RC for BCa in 208 hospitals in the USA from 2003 to 2015 in the Premier Healthcare Database.
Ninety-day direct hospital costs; multilevel hierarchal linear models were constructed to evaluate contributions of each variable to costs.
Mean 90-d direct hospital costs per RC was $39 651 (standard deviation $34 427), of which index hospitalization accounted for 87.8% ($34 803) and postdischarge readmission(s) accounted for 12.2% ($4847). Postoperative complications contributed most to cost variations (84.5%), followed by patient (49.8%; eg, Charlson Comorbidity Index [CCI], 40.5%), surgical (33.2%; eg, year of surgery [25.0%]), and hospital characteristics (8.0%). Patients who suffered minor complications (odds ratio [OR] 2.63, 95% confidence interval [CI]: 2.03-3.40), nonfatal major complications (OR 12.7, 95% CI: 9.63-16.8), and mortality (OR 13.5, 95% CI: 9.35-19.4, all p<0.001) were significantly associated with high costs. As for low-cost surgery, sicker patients (CCI=2: OR 0.41, 95% CI: 0.29-0.59; CCI=1: OR 0.58, 95% CI: 0.46-0.75, both p<0.001), those who underwent continent diversion (vs incontinent diversion: OR 0.29, 95% CI: 0.16-0.53, p<0.001), and earlier period of surgery were inversely associated with low costs.
This study provides insight into the determinants of costs for RC. Postoperative morbidity, patient comorbidities, and year of surgery contributed most to observed variations in costs, while other hospital- and surgical-related characteristics such as volume, use of robot assistance, and type of urinary diversion contribute less to outlier costs.
Efforts to address high surgical cost must be tailored to specific determinants of high and low costs for each operation. In contrast to robot-assisted radical prostatectomy where surgeon factors predominate, high costs in radical cystectomy were primarily determined by postoperative complication and patient comorbidities.
根治性膀胱切除术(RC)治疗肌层浸润性膀胱癌(BCa)有发生严重并发症、住院时间延长和再入院的风险,所有这些都可能增加费用。虽然结局的差异已有详细描述,但对于导致费用差异的决定因素了解较少。
评估外科医生和医院层面的费用差异以及高成本和低成本RC的预测因素。
设计、设置和参与者:对2003年至2015年在美国208家医院的Premier医疗数据库中因BCa接受RC的23173例患者进行队列研究。
90天直接医院费用;构建多级分层线性模型以评估每个变量对费用的贡献。
每例RC的90天直接医院平均费用为39651美元(标准差34427美元),其中首次住院占87.8%(34803美元),出院后再入院占12.2%(4847美元)。术后并发症对费用差异的贡献最大(84.5%),其次是患者因素(49.8%;如Charlson合并症指数[CCI],占40.5%)、手术因素(33.2%;如手术年份[占25.0%])和医院特征(8.0%)。发生轻微并发症(比值比[OR]2.63,95%置信区间[CI]:2.03 - 3.40)、非致命性严重并发症(OR 12.7,95% CI:9.63 - 16.8)和死亡(OR 13.5,95% CI:9.35 - 19.4,均p<0.001)的患者与高费用显著相关。对于低成本手术,病情较重的患者(CCI = 2:OR 0.41,95% CI:0.29 - 0.59;CCI = 1:OR 0.58,95% CI:0.46 - 0.75,均p<0.001)、接受可控性尿流改道的患者(与不可控性尿流改道相比:OR 0.29,95% CI:0.16 - 0.53,p<0.001)以及手术时间较早的患者与低费用呈负相关。
本研究深入了解了RC费用的决定因素。术后发病率、患者合并症和手术年份对观察到的费用差异贡献最大,而其他与医院和手术相关的特征,如手术量、机器人辅助的使用和尿流改道类型对异常费用的贡献较小。
应对高手术费用的努力必须针对每种手术高成本和低成本的特定决定因素进行调整。与以外科医生因素为主的机器人辅助根治性前列腺切除术不同,根治性膀胱切除术的高成本主要由术后并发症和患者合并症决定。